Evaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast Cancer
Conditions
Keywords
neoadjuvant chemotherapy, Mammaprint, blueprint, prognosis
Brief summary
This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the technical analysis of Mammaprint in patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in tumor tissues and evaluated the accuracy and sensitivity of Mammaprint test in the efficacy of neoadjuvant chemotherapy.A new model for predicting NCT effect of breast cancer with combined risk genes and clinical parameters was established based on the clinical characteristic parameters of patients to study the accuracy and sensitivity of Mammaprint monitoring for prognosis determination of breast cancer patients.
Interventions
COMBINATION_PRODUCTneoadjuvant chemotherapy
This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the Mammaprint technology analysis of patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in the tumor tissues and evaluated the accuracy and sensitivity of the Mammaprint test for the efficacy of neoadjuvant chemotherapy
Sponsors
Zhejiang Cancer Hospital
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
25 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Pathologically confirmed new breast cancer (invasive cancer) * Clinical stage II-III * women * Aged 25-80 * At least 6 months of follow-up data, clinical diagnosis and treatment information and personal information available for follow-up are complete * Complete biological samples required for the study: fresh/frozen tissues/white tablets/wax blocks meeting the requirements of the experiment (before neoadjuvant chemotherapy) * Tumor markers and imaging data were complete * Neoadjuvant chemotherapy is commonly recommended by the standard NCCN guidelines
Exclusion criteria
* Subjects refuse to participate * First diagnosis of stage I or IV breast cancer * Pathological diagnosis of concurrent (or previous) other malignant tumors * Prehistory breast cancer * Younger than 25 or older than 80 * Clinical diagnosis and treatment information or biological samples required by the research institute do not meet the needs of the experiment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence Score variation after neoadjuvant chemotherapy | 6 months | The recurrence score of each subtype |
Countries
China
Contacts
Primary ContactXing fei Yu, doctoral degree
Outcome results
None listed